Zacks Investment Research Upgrades USANA Health Sciences (NYSE:USNA) to “Hold”

USANA Health Sciences (NYSE:USNAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “

Several other analysts have also weighed in on the company. TheStreet lowered USANA Health Sciences from a “b” rating to a “c+” rating in a report on Wednesday, February 9th. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Finally, DA Davidson lowered their target price on USANA Health Sciences from $86.00 to $76.00 in a report on Wednesday, April 27th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, USANA Health Sciences has a consensus rating of “Buy” and a consensus target price of $105.00.

NYSE:USNA opened at $74.28 on Friday. USANA Health Sciences has a one year low of $71.19 and a one year high of $107.85. The business’s 50-day simple moving average is $80.73 and its 200 day simple moving average is $92.10. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 13.73 and a beta of 0.84.

USANA Health Sciences (NYSE:USNAGet Rating) last released its quarterly earnings results on Tuesday, April 26th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. USANA Health Sciences had a return on equity of 27.04% and a net margin of 9.41%. During the same period in the previous year, the business earned $1.45 EPS. As a group, equities research analysts expect that USANA Health Sciences will post 5.28 EPS for the current fiscal year.

In other USANA Health Sciences news, insider Joshua Foukas sold 3,303 shares of the company’s stock in a transaction dated Wednesday, March 2nd. The shares were sold at an average price of $89.93, for a total transaction of $297,038.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert A. Fuller sold 312 shares of the company’s stock in a transaction dated Tuesday, February 15th. The shares were sold at an average price of $89.62, for a total transaction of $27,961.44. The disclosure for this sale can be found here. Insiders have sold a total of 6,653 shares of company stock valued at $600,825 in the last quarter. Insiders own 0.36% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hussman Strategic Advisors Inc. lifted its stake in shares of USANA Health Sciences by 4.8% in the first quarter. Hussman Strategic Advisors Inc. now owns 26,000 shares of the company’s stock valued at $2,066,000 after buying an additional 1,200 shares during the period. Victory Capital Management Inc. lifted its stake in shares of USANA Health Sciences by 54.2% in the first quarter. Victory Capital Management Inc. now owns 8,083 shares of the company’s stock valued at $620,000 after buying an additional 2,840 shares during the period. Gladius Capital Management LP lifted its stake in USANA Health Sciences by 20.2% during the first quarter. Gladius Capital Management LP now owns 905 shares of the company’s stock worth $72,000 after purchasing an additional 152 shares during the period. Exchange Traded Concepts LLC lifted its stake in USANA Health Sciences by 11.4% during the first quarter. Exchange Traded Concepts LLC now owns 20,928 shares of the company’s stock worth $1,663,000 after purchasing an additional 2,148 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its stake in USANA Health Sciences by 10.7% during the first quarter. Robeco Institutional Asset Management B.V. now owns 25,529 shares of the company’s stock worth $2,028,000 after purchasing an additional 2,474 shares during the period. Institutional investors and hedge funds own 55.72% of the company’s stock.

About USANA Health Sciences (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Further Reading

Get a free copy of the Zacks research report on USANA Health Sciences (USNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.